Habjanič N, et al. - In patients with mild to moderate plaque psoriasis, researchers explored the potential connection between the baseline features of patients and the effectiveness of calcipotriol-betamethasone ointment and assessed whether the effectiveness is consistent across subgroups. They conducted post hoc analyses using data from the therapeutic equivalence study on patients with plaque psoriasis to assess the effect of baseline demographic and disease characteristics, habits and comorbidities on the response to treatment with calcipotriol-betamethasone ointment. According to results, BMI and obesity were each independently linked to decline in modified Psoriasis Area and Severity Index (mPASI) and PASI75 (≥75% improvement in mPASI from baseline). In patients with late-onset psoriasis, increased body weight is more prevalent. A significant trend was found for lower response rates with increasing BMI and obesity. Compared with normal-weight individuals, the odds of achieving PASI75 is 2.3 times lower for obese. If obesity or hypertension patients were treated with calcipotriol-betamethasone, they were still more likely to achieve PASI75 compared with the vehicle after 4-week treatment. The authors concluded that increased BMI and obesity are presenting risk factors for reduced efficacy of treatment. Importantly, in all subgroups, the effectiveness of calcipotriol-betamethasone ointment was consistent.